Evidence map›Paper›PMID 42027810›Full record

ArticleBioactive materials2026

Intelligent plant exosomes synergize miRNAs and cisplatin for spatiotemporally precise multimodal treatment for TNBC with high safety.

Xi-Yuan Xu, Xuan Zhang, Yi-Yi Wang, Qi-Yao Xiao, Cheng Yang, De-Sheng Kong, Li-Hua Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xi-Yuan XuCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Xuan ZhangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Yi-Yi WangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Qi-Yao XiaoCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Cheng YangCollege of Engineering and Applied Sciences, and State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, 210023, PR China.
De-Sheng KongCollege of Engineering and Applied Sciences, and State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, 210023, PR China.
Li-Hua PengCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) lacks common receptors and exhibits aggressive behavior, limiting treatment options due to drug resistance and systemic toxicity. TNBC chemotherapy is hindered by poor tumor targeting, drug resistance, and systemic toxicity. Herein, this study presented a cascade targeting exosomal-cisplatin synergistic microneedle nanoplatform (CDDP@RKTExo-MN) as an intelligent wearable therapeutic device for TNBC treatment. Medicinal plant

Indexed as

CisplatinPlant exosome engineeringTransdermal-cascade targeting programmed deliveryTriple-negative breast cancerWearable microneedle patch

Identifiers

PMID42027810
PMCPMC13099513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.